ArticleLeukemia2009
A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability.
B ten Cate et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
31 papers cite it
this papercites it